Dr. Barry Heller, M.D.
Emergency Medicine (Emergency Medicine Physician)
1050 Linden Ave
Long Beach, CA 90813
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
Licensed in California since 1980, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Emergency Medicine Physician primary
CA license C39263 (first issued 1980; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $748,228 in research payments for these studies, mostly to the institutions running them.
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
Sanofi Pasteur Inc. · Completed · NCT06361875 - A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT05330975 - Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older
Sanofi Pasteur Inc. · Completed · NCT05624606 - A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With …
Janssen Research & Development, LLC - NB (Contrave) Cardiovascular Outcomes Trial
Currax Pharmaceuticals LLC - An interventional efficacy and safety phase 3 doubleblind 2ARM study to investigate orally administered ibuzatrelvir compared with placebo in nonhospitalized symptomatic adult and adolescent participants with COVID19 …
Pfizer Inc. - A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
Teva Pharmaceuticals USA, Inc. - Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older
Sanofi Pasteur Inc. · Completed · NCT05650554
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.